EGFR-TKI治疗非小细胞肺癌中枢神经系统转移的进展

Approximately half of all patients with non-small cell lung cancer (NSCLC) develop central nervous system metastases during the course of their disease which indicate poor prognosis. A part of NSCLC patients demonstrates activating epidermal growth factor receptor gene (EGFR) mutations who represent effectiveness and well tolerance of EGFRspecific tyrosine kinase inhibitors (TKIs) therapy. Although the systemic efcacy of targeted agents is established, the efcacy of central nervous system (CNS) metastases is not as well characterized. In this article, we review recent data on the use of EGFR inhibitors for treatment of patients with NSCLC and CNS metastases.